Breaking Through – Medherant’s Professor David Haddleton and Dr Vasiliki Nikolaou discuss transdermal drug delivery systems in Innovations in Pharmaceutical Technology
There are many problems linked to oral drug administration including first pass metabolism, gastrointestinal tract damage and low levels of drug reaching the target site. Trying to overcome these is an important area of research across the pharmaceut...
Transdermal Delivery of Ibuprofen Utilizing a Novel Solvent-Free Pressure-sensitive Adhesive (PSA): TEPI® Technology
The Journal of Pharmaceutical Innovation, Springer, has published the research paper 'Transdermal Delivery of Ibuprofen Utilizing a Novel Solvent-Free Pressure-sensitive Adhesive (PSA): TEPI® Technology', authored by Medherant staff members Emm...
Medherant completes £3.8 million funding round
Coventry, UK, 11th December 2017 / Medherant, a leader in next-generation transdermal drug delivery, has raised £3.8 million in its latest funding round. The fundraising was led by majority shareholder Mercia Technologies PLC, with the balance ...
Medherant wins Excellence in Science & Technology Award
Medherant is delighted to announce they have been awarded the ‘Excellence in Science & Technology Award’ at the Coventry Telegraph Business Awards last night. These Awards are a celebration of companies in Coventry and Warwicks...
Medherant signs agreement with leading Japanese transdermal patch company for evaluation of its TEPI Patch® drug delivery system
Coventry, UK, 27th September 2017 / Medherant, a leader in next-generation transdermal drug delivery, has signed an agreement with a Japanese transdermal patch company (“the company”), one of the world’s largest patch developers and manufa...
Medherant expands management team with appointment of Sally Waterman, COO and Angus Hone, CFO
Coventry, UK, 26th June 2017 / Medherant Ltd, a University of Warwick spin-out company developing a next-generation transdermal drug delivery patch technology, is pleased to announce the appointment of two new senior executives, Sally Waterman and An...
Medherant shortlisted for Royal Society of Chemistry Emerging Technologies competition
Coventry, UK, 12th June 2017 / Medherant Ltd, a University of Warwick spin-out company developing a novel transdermal drug delivery patch technology, has been chosen as one of 40 companies shortlisted for the Royal Society of Chemistry (RSC) Eme...
Medherant Appoints Sheryl Caswell to Lead Clinical Development of Products Based on its Revolutionary TEPI Patch®
Coventry, UK, 6th June 2017 / Medherant Ltd, a University of Warwick spin-out company developing a novel transdermal drug delivery patch technology, is pleased to announce the appointment of Sheryl Caswell as Head of Clinical Development. Sheryl...
Medherant Appoints Laboratoires Plasto Santé as Transdermal Drug Delivery Patch Manufacturer
Coventry, UK, 8th May 2017 / Medherant Ltd, a University of Warwick spin-out company developing a novel transdermal drug delivery patch technology, has appointed Laboratoires Plasto Santé to manufacture its first drug delivery patches. The f...